An Open Label Study of FT218 in Subjects With Narcolepsy
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
An Open Label Study to Evaluate Long-Term Safety and Tolerability of a Once Nightly
Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) and the ability to
switch from twice-nightly immediate release sodium oxybate to once-nightly FT218 for the
Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects with Narcolepsy